BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11389188)

  • 21. Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site.
    Dickson DW; Ksiezak-Reding H; Liu WK; Davies P; Crowe A; Yen SH
    Acta Neuropathol; 1992; 84(6):596-605. PubMed ID: 1281953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's disease.
    Bondareff W; Harrington CR; Wischik CM; Hauser DL; Roth M
    J Neuropathol Exp Neurol; 1995 Sep; 54(5):657-63. PubMed ID: 7666054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical evidence for reorganization of tau in the plaques and tangles in Alzheimer's disease.
    Wood JG; Zinsmeister P
    Histochem J; 1989 Nov; 21(11):659-62. PubMed ID: 2511165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease.
    Schmidt ML; DiDario AG; Lee VM; Trojanowski JQ
    FEBS Lett; 1994 May; 344(1):69-73. PubMed ID: 8181568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer's disease PHFtau.
    Schmidt ML; Huang R; Martin JA; Henley J; Mawal-Dewan M; Hurtig HI; Lee VM; Trojanowski JQ
    J Neuropathol Exp Neurol; 1996 May; 55(5):534-9. PubMed ID: 8627344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics.
    Rosseels J; Van den Brande J; Violet M; Jacobs D; Grognet P; Lopez J; Huvent I; Caldara M; Swinnen E; Papegaey A; Caillierez R; Buée-Scherrer V; Engelborghs S; Lippens G; Colin M; Buée L; Galas MC; Vanmechelen E; Winderickx J
    J Biol Chem; 2015 Feb; 290(7):4059-74. PubMed ID: 25540200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.
    Goedert M; Jakes R; Crowther RA; Cohen P; Vanmechelen E; Vandermeeren M; Cras P
    Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):871-7. PubMed ID: 7519852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of the carboxyl terminal sequence of tau in ghost tangles of Alzheimer's disease.
    Endoh R; Ogawara M; Iwatsubo T; Nakano I; Mori H
    Brain Res; 1993 Jan; 601(1-2):164-72. PubMed ID: 8431763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein.
    Philippe B; Brion JP; Coppens E; Octave JN
    J Neurosci Res; 1996 Dec; 46(6):709-19. PubMed ID: 8978505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of tau proteins in Alzheimer's disease. Evidence for increased expression of an isoform and preferential distribution of a phosphorylated isoform in neurites.
    Liu WK; Dickson DW; Yen SH
    Am J Pathol; 1993 Feb; 142(2):387-94. PubMed ID: 7679548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology.
    Carmel G; Mager EM; Binder LI; Kuret J
    J Biol Chem; 1996 Dec; 271(51):32789-95. PubMed ID: 8955115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormally phosphorylated tau protein in Alzheimer's disease: heterogeneity of individual regional distribution and relationship to clinical severity.
    Holzer M; Holzapfel HP; Zedlick D; Brückner MK; Arendt T
    Neuroscience; 1994 Nov; 63(2):499-516. PubMed ID: 7891861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Human tau N-terminal domain-specific monoclonal antibodies: screening and application in blood detection].
    Yan Z; Zhang Y; Jiang J; Liu Z; Wang H; Zhang Y; He J; Hong T
    Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1571-1583. PubMed ID: 38783817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of TauC3 antibody and demonstration of its potential to block tau propagation.
    Nicholls SB; DeVos SL; Commins C; Nobuhara C; Bennett RE; Corjuc DL; Maury E; Eftekharzadeh B; Akingbade O; Fan Z; Roe AD; Takeda S; Wegmann S; Hyman BT
    PLoS One; 2017; 12(5):e0177914. PubMed ID: 28531180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The N terminal region of human tau is present in Alzheimer's disease protein A68 and is incorporated into paired helical filaments.
    Crowe A; Ksiezak-Reding H; Liu WK; Dickson DW; Yen SH
    Am J Pathol; 1991 Dec; 139(6):1463-70. PubMed ID: 1721492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological memory to hyperphosphorylated tau in asymptomatic individuals.
    Pascual G; Wadia JS; Zhu X; Keogh E; Kükrer B; van Ameijde J; Inganäs H; Siregar B; Perdok G; Diefenbach O; Nahar T; Sprengers I; Koldijk MH; der Linden EC; Peferoen LA; Zhang H; Yu W; Li X; Wagner M; Moreno V; Kim J; Costa M; West K; Fulton Z; Chammas L; Luckashenak N; Fletcher L; Holland T; Arnold C; Anthony Williamson R; Hoozemans JJ; Apetri A; Bard F; Wilson IA; Koudstaal W; Goudsmit J
    Acta Neuropathol; 2017 May; 133(5):767-783. PubMed ID: 28341999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease.
    Ghoshal N; García-Sierra F; Wuu J; Leurgans S; Bennett DA; Berry RW; Binder LI
    Exp Neurol; 2002 Oct; 177(2):475-93. PubMed ID: 12429193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease.
    García-Sierra F; Ghoshal N; Quinn B; Berry RW; Binder LI
    J Alzheimers Dis; 2003 Apr; 5(2):65-77. PubMed ID: 12719624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.